Țară: Taiwan
Limbă: chineză
Sursă: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
ALPROSTADIL (PGE1)
台灣微脂體股份有限公司 台北市南港區園區街3號11樓之1 (16176150)
C01EA01
注射劑
ALPROSTADIL (PGE1) (6832001600) ug
安瓿;;盒裝
製 劑
限由醫師使用
杏林新生製藥股份有限公司 桃園市龍潭區三和村店湖一路237號 TW
alprostadil
週邊動脈阻塞疾病症狀改善。
註銷日期: 2023/07/27; 註銷理由: 未展延而逾期者; 有效日期: 2019/12/22; 英文品名: ProFlow Injection 5 μg/mL
已註銷
2010-12-22
- 1 - 普絡易 ® 注射液 5 微克 / 毫升 ProFlow® Injection 5μg/mL As prescribed by physician Storage : Between 2 and 8 ℃ Expiry date: See the outer package 【 CONTRAINDICATIONS 】 PROFLOW® IS CONTRAINDICATED TO THE FOLLOWING PEOPLE: 1. PATIENTS WITH SERIOUS HEART FAILURE. (THE EXACERBATION OF HEART FAILURE HAS BEEN REPORTED.) 2. PATIENT WITH HEMORRHAGE (INTRACRANIAL HEMORRHAGE, DIGESTIVE TRACT HEMORRHAGE, HEMOPTYSIS, ETC.) [HEMORRHAGE MAY BE PROMOTED.] 3. PREGNANT WOMEN OR WOMEN WHO MAY POSSIBLE BE PREGNANT. (SEE “USE DURING PREGNANT, PUERPERAL OR LACTATION SECTION”) 4. PATIENTS WHO HAVE DEMONSTRATED OR HAVE KNOWN HYPERSENSITIVITY TO ANY INGREDIENT OF PROFLOW® . 【 DESCRIPTION 】 ProFlow® Injection 5μg/mL is a white, slightly viscous and peculiar odor emulsion, having a pH of 4.5–6.0, the osmotic pressure ration (to physiological saline) is approximate 1. ACTIVE SUBSTANCE: Each 1mL ProFlow® contains Alprostadil 5μg Each 2mL ProFlow® contains Alprostadil 10μg EXCIPIENT: Medium-chain triglycerides, purified yolk lecithin, polysorbate 80, concentrated glycerin, hydrochloric acid, sodium hydroxide, water for injection. 【 INDICATIONS 】 Improvement of peripheral arterial occlusion disease. 【 DOSAGE AND ADMINISTRATION 】 For adult patients, the recommended daily dose is 1mL to 2mL (5 to 10μg of alprostadil) either without mixing or dilution, or as an admixture with an infusion solution, by intravenous infusion for at least 5 minutes. PRECAUTION FOR ADMINISTRATION Do not use this product in admixtures with drugs other than infusion solutions. Avoid diluting with plasma expanders (dextran, gelatin preparations, etc.) When ProFlow® is administered by intravenous infusion, make sure to use a infusion line separately to prevent aggregation within the line. 【 PRECAUTIONS 】 1. PROFLOW® SHOULD BE ADMINISTERED IN THE FOLLOWING PATIENTS CAREFULLY: (1) PATIENTS WITH HEART FAILURE. (HEART FAILURE MAY BE AGGRAVATED.) (2) PATIENTS WITH HEMORRHAGE. (HEMORRHAGE MAY BE PROMOTED.) (3) PATIENTS Citiți documentul complet